FDA Approval: Novel Formulation for Treatment of Schizophrenia

September 11, 2024

Driving FDA Approvals with Precision and Speed

Discover how CRC’s expertise in clinical trial management supported the FDA approval of a novel formulation for schizophrenia treatment. Download the full case study to explore the challenges faced, proactive solutions implemented, and the strategic approach that delivered results on time and on budget.

< Older Post

Newer Post >
Dementia patient and doctor in clinical setting related to agitation trial

Mastering Agitation Endpoints with Assessment Expertise

July 30, 2025
Discover how CRC managed rater complexity and timelines in an agitation study using customized training and algorithmic oversight.
Alzheimer's patient with doctor

Seamless Execution Across Early-Phase Alzheimer’s Trials

July 15, 2025
Discover how CRC supported a novel Alzheimer’s program through first-in-human (FIH), Phase Ib/IIa, and OLE trials with precision, urgency, and trusted oversight.
Illustration of active brain neurons highlighting neural pathways

The Expanding Role of GLP-1 Receptor Agonists in CNS Clinical Research

July 1, 2025
GLP-1 receptor agonists may offer a new path for treating addiction and mental health challenges, emerging as a versatile class in CNS clinical research.
Show More